Tocqueville Asset Management L.P. Makes New $5.37 Million Investment in Edwards Lifesciences Corporation $EW

Key Points

• Tocqueville Asset Management purchased 59,400 Edwards Lifesciences shares worth approximately $5.37 million during the second quarter. Institutional investors collectively own 79.46% of the company.
• Edwards Lifesciences exceeded quarterly expectations, reporting $0.78 in EPS versus the $0.74 estimate and $1.74 billion in revenue, up 13.6% year over year. The company issued third-quarter 2026 EPS guidance of $0.71–$0.77.
• Analyst sentiment is favorable, with 17 Buy ratings and six Hold ratings, producing a consensus “Moderate Buy” rating and an average price target of $100.27 versus the reported share price of $90.02.

Tocqueville Asset Management L.P. purchased a new position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 59,400 shares of the medical research company's stock, valued at approximately $5,373,000.

A number of other large investors have also made changes to their positions in EW. BlackRock Inc. purchased a new stake in Edwards Lifesciences during the second quarter worth about $5,318,092,000. State Street Corp increased its holdings in Edwards Lifesciences by 1.5% in the fourth quarter. State Street Corp now owns 25,991,524 shares of the medical research company's stock valued at $2,215,777,000 after buying an additional 371,892 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Edwards Lifesciences by 4.8% during the 4th quarter. Wellington Management Group LLP now owns 21,793,949 shares of the medical research company's stock valued at $1,857,934,000 after acquiring an additional 989,533 shares during the period. Bank of New York Mellon Corp acquired a new stake in shares of Edwards Lifesciences during the 2nd quarter valued at approximately $1,274,082,000. Finally, Norges Bank purchased a new stake in shares of Edwards Lifesciences during the 4th quarter worth approximately $803,686,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Stock Performance

Shares of NYSE EW opened at $90.02 on Friday. The company has a market cap of $51.83 billion, a PE ratio of 51.74, a price-to-earnings-growth ratio of 2.32 and a beta of 0.85. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $96.29. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77. The company has a 50-day simple moving average of $89.12 and a 200-day simple moving average of $84.63.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.04. The business had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The company's quarterly revenue was up 13.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, equities analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 619 shares of the firm's stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total transaction of $56,966.57. Following the sale, the vice president owned 40,034 shares in the company, valued at $3,684,329.02. This trade represents a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of Edwards Lifesciences stock in a transaction on Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the completion of the sale, the senior vice president directly owned 15,334 shares of the company's stock, valued at approximately $1,319,950.72. This represents a 3.57% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 25,570 shares of company stock worth $2,219,390. Insiders own 0.31% of the company's stock.

Analyst Ratings Changes

A number of research firms recently weighed in on EW. Leerink Partners upgraded Edwards Lifesciences from a "market perform" rating to an "outperform" rating and upped their price target for the stock from $87.00 to $101.00 in a report on Friday, July 24th. BTIG Research lifted their price objective on Edwards Lifesciences from $100.00 to $110.00 and gave the stock a "buy" rating in a report on Tuesday, June 30th. Robert W. Baird boosted their target price on Edwards Lifesciences from $85.00 to $87.00 and gave the stock a "neutral" rating in a research report on Friday, April 24th. Weiss Ratings reissued a "hold (c)" rating on shares of Edwards Lifesciences in a report on Friday, July 17th. Finally, Piper Sandler reissued an "overweight" rating and issued a $101.00 target price (up from $100.00) on shares of Edwards Lifesciences in a report on Friday, July 24th. Seventeen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $100.27.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source